Transpharmation Logo
  • Contact Us

Models & Assays

Novelty Suppressed Feeding Test

The Novelty Suppressed Feeding test (NSF), which is based on hyponeophagia (a phenomenon where exposure to a novel environment suppresses feeding behavior), has been used extensively to assess anxiety-related behavior in mice. The NSF test is an effective behavioral paradigm for evaluating the efficacy of treatments with drugs such as anxiolytics and antidepressants, as their administration result in a decrease in the time (latency) needed by animal to initiate feeding in the novel, anxiogenic environment.

To validate the efficacy of the NSF test, our research team performed studies on C57BL/6 female and male mice (7-9 weeks old) using a varying doses of diazepam as an anxiolytic substance. The results clearly demonstrated efficacy of diazepam (0.5 mg/kg, i.p.) in reducing anxiety-like behavior in both female and male mice observed 30 minutes post-administration in the NSF test.


  1. Iijima M, Fukumoto K, Chaki S. Acute and sustained effects of a metabotropic glutamate 5 receptor antagonist in the novelty-suppressed feeding test. Behav Brain Res. 2012 Dec 1;235(2):287-92.
  2. Samuels, B.A., Hen, R. (2011). Novelty-Suppressed Feeding in the Mouse. In: Gould, T. (eds) Mood and Anxiety Related Phenotypes in Mice. Neuromethods, vol 63. Humana Press.

Company

  • Our Team
  • Publications
  • News
  • Careers
  • Animal Welfare
  • Privacy Policy
  • Accessibility Policy
  • Cookies Policy

Services

  • Abuse Liability / Substance Use Disorders
  • Alzheimer's Disease
  • Bioanalytical Studies
  • CNS Drug Disposition
  • Cognitive Assessment
  • Depression/Anxiety
  • Dermatology
  • EEG
  • Epilepsy
  • Essential Tremor
  • Imaging
  • Inflammatory Pain
  • Inflammation
  • Medical Cannabis
  • Metabolic Disorders
  • Migraine
  • Molecular Biomarkers
  • Multiple Sclerosis
  • Neuropathic Pain
  • Operant Platform
  • Osteoarthritis
  • Parkinson's Disease
  • PK/PD Studies
  • PK-Bridge
  • Psychedelics
  • PXB Mouse Studies
  • Safety Studies
  • Schizophrenia
  • Veterinary Research
North America
1-548-538-2371
Europe
+44 (0)130 440 3165
Contact us

© 2024 Transpharmation™. All Rights Reserved.
Sitemap
LinkedIn account
Youtube account